Oral Antiplatelet Therapy in Acute Coronary Syndromes: Recent Developments View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-06

AUTHORS

Uwe Zeymer

ABSTRACT

The purpose of this article is to summarize the current knowledge about treatment with oral platelet inhibitors in patients with acute coronary syndrome (ACS). Antiplatelet therapy has been shown to improve the prognosis of patients with ACS with ST segment elevation myocardial infarction (STEMI) and non-ST segment elevation ACS (NSTE-ACS). Aspirin should be given with a loading dose of 250-500 mg, followed by 75-100 mg/day. Dual antiplatelet therapy is recommended for all patients with ACS for 12 months regardless of the initial revascularization strategy. Clopidogrel should be administered at first medical contact in STEMI with a loading dose of 600 mg. In patients with ACS and percutaneous coronary intervention (PCI) 2 × 75 mg clopidogrel should be given daily over 7 days, while in all other patients 75 mg per day appears to be sufficient. The two newer adenosine diphosphate-receptor antagonists prasugrel and ticagrelor lead to a more rapid and effective inhibition of platelet aggregation compared with clopidogrel, which was associated with an improved clinical outcome in two large randomized studies. Prasugrel is indicated in patients with ACS undergoing PCI and was most effective in diabetics and in patients with STEMI. In the recent TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial in medically treated patients with NSTE-ACS, prasugrel did not significantly reduce ischemic events compared with clopidogrel. Ticagrelor has been studied in the whole spectrum of ACS patients and reduced cardiovascular and total mortality in comparison with clopidogrel. The greatest benefit has been observed in patients with planned conservative treatment and in patients with impaired renal function. Expanding antiplatelet therapy from dual to triple therapy including a platelet thrombin receptor antagonist in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial was not associated with a significant reduction in the primary combined endpoint but an increase in bleeding complications. However, in the Thrombin Receptor Antagonist in Secondary Prevention of atherothrombotic ischemic events study in patients with prior myocardial infarction, vorapaxar on top of standard antiplatelet therapy was effective. More... »

PAGES

47-56

Journal

TITLE

Cardiology and Therapy

ISSUE

1

VOLUME

2

Author Affiliations

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40119-013-0011-6

DOI

http://dx.doi.org/10.1007/s40119-013-0011-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1003526860

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25135288


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Klinikum Ludwigshafen", 
          "id": "https://www.grid.ac/institutes/grid.413225.3", 
          "name": [
            "Klinikum der Stadt Ludwigshafen GmbH, Bremserstra\u00dfe 79, 67063, Ludwigshafen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zeymer", 
        "givenName": "Uwe", 
        "id": "sg:person.01206257120.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01206257120.28"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1056/nejmoa0706482", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000755110"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1205512", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001300580"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1209979", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013847757"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circulationaha.110.000786", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014740796"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehr236", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016275826"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ahj.2010.04.008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018883623"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehr143", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018934044"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0909475", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020098070"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehr202", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021747503"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jacc.2010.03.100", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022669837"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circulationaha.109.933796", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023849780"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(12)61269-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024204479"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(09)60441-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024369135"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(10)61088-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026699485"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehr204", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035258191"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0904327", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038668813"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(10)61273-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038812925"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmra052717", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040996314"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jacc.2006.04.090", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042022467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa010746", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042739677"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ahj.2009.10.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043980215"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/circulationaha.108.791061", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045157062"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00392-011-0393-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047301868", 
          "https://doi.org/10.1007/s00392-011-0393-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehq320", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047347722"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehq320", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047347722"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1109719", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047539071"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/cir.0b013e318256f1e0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052130924"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/cir.0b013e318256f1e0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052130924"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jacc.2010.10.029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052574621"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1160/th09-07-0482", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063292175"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-06", 
    "datePublishedReg": "2013-06-01", 
    "description": "The purpose of this article is to summarize the current knowledge about treatment with oral platelet inhibitors in patients with acute coronary syndrome (ACS). Antiplatelet therapy has been shown to improve the prognosis of patients with ACS with ST segment elevation myocardial infarction (STEMI) and non-ST segment elevation ACS (NSTE-ACS). Aspirin should be given with a loading dose of 250-500\u00a0mg, followed by 75-100\u00a0mg/day. Dual antiplatelet therapy is recommended for all patients with ACS for 12\u00a0months regardless of the initial revascularization strategy. Clopidogrel should be administered at first medical contact in STEMI with a loading dose of 600\u00a0mg. In patients with ACS and percutaneous coronary intervention (PCI) 2\u00a0\u00d7\u00a075\u00a0mg clopidogrel should be given daily over 7\u00a0days, while in all other patients 75\u00a0mg per day appears to be sufficient. The two newer adenosine diphosphate-receptor antagonists prasugrel and ticagrelor lead to a more rapid and effective inhibition of platelet aggregation compared with clopidogrel, which was associated with an improved clinical outcome in two large randomized studies. Prasugrel is indicated in patients with ACS undergoing PCI and was most effective in diabetics and in patients with STEMI. In the recent TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial in medically treated patients with NSTE-ACS, prasugrel did not significantly reduce ischemic events compared with clopidogrel. Ticagrelor has been studied in the whole spectrum of ACS patients and reduced cardiovascular and total mortality in comparison with clopidogrel. The greatest benefit has been observed in patients with planned conservative treatment and in patients with impaired renal function. Expanding antiplatelet therapy from dual to triple therapy including a platelet thrombin receptor antagonist in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial was not associated with a significant reduction in the primary combined endpoint but an increase in bleeding complications. However, in the Thrombin Receptor Antagonist in Secondary Prevention of atherothrombotic ischemic events study in patients with prior myocardial infarction, vorapaxar on top of standard antiplatelet therapy was effective. ", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40119-013-0011-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1050274", 
        "issn": [
          "2193-8261", 
          "2193-6544"
        ], 
        "name": "Cardiology and Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "2"
      }
    ], 
    "name": "Oral Antiplatelet Therapy in Acute Coronary Syndromes: Recent Developments", 
    "pagination": "47-56", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "10cd095c274933c87c5b1c3779e5738c498aff8e6548016334a412503151cd7d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25135288"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101634495"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40119-013-0011-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1003526860"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40119-013-0011-6", 
      "https://app.dimensions.ai/details/publication/pub.1003526860"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T21:38", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8687_00000520.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs40119-013-0011-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40119-013-0011-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40119-013-0011-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40119-013-0011-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40119-013-0011-6'


 

This table displays all metadata directly associated to this object as RDF triples.

154 TRIPLES      21 PREDICATES      57 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40119-013-0011-6 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N84cb2fa864364df8811cc68dac1d7dd1
4 schema:citation sg:pub.10.1007/s00392-011-0393-1
5 https://doi.org/10.1016/j.ahj.2009.10.010
6 https://doi.org/10.1016/j.ahj.2010.04.008
7 https://doi.org/10.1016/j.jacc.2006.04.090
8 https://doi.org/10.1016/j.jacc.2010.03.100
9 https://doi.org/10.1016/j.jacc.2010.10.029
10 https://doi.org/10.1016/s0140-6736(09)60441-4
11 https://doi.org/10.1016/s0140-6736(10)61088-4
12 https://doi.org/10.1016/s0140-6736(10)61273-1
13 https://doi.org/10.1016/s0140-6736(12)61269-0
14 https://doi.org/10.1056/nejmoa010746
15 https://doi.org/10.1056/nejmoa0706482
16 https://doi.org/10.1056/nejmoa0904327
17 https://doi.org/10.1056/nejmoa0909475
18 https://doi.org/10.1056/nejmoa1109719
19 https://doi.org/10.1056/nejmoa1205512
20 https://doi.org/10.1056/nejmoa1209979
21 https://doi.org/10.1056/nejmra052717
22 https://doi.org/10.1093/eurheartj/ehq320
23 https://doi.org/10.1093/eurheartj/ehr143
24 https://doi.org/10.1093/eurheartj/ehr202
25 https://doi.org/10.1093/eurheartj/ehr204
26 https://doi.org/10.1093/eurheartj/ehr236
27 https://doi.org/10.1160/th09-07-0482
28 https://doi.org/10.1161/cir.0b013e318256f1e0
29 https://doi.org/10.1161/circulationaha.108.791061
30 https://doi.org/10.1161/circulationaha.109.933796
31 https://doi.org/10.1161/circulationaha.110.000786
32 schema:datePublished 2013-06
33 schema:datePublishedReg 2013-06-01
34 schema:description The purpose of this article is to summarize the current knowledge about treatment with oral platelet inhibitors in patients with acute coronary syndrome (ACS). Antiplatelet therapy has been shown to improve the prognosis of patients with ACS with ST segment elevation myocardial infarction (STEMI) and non-ST segment elevation ACS (NSTE-ACS). Aspirin should be given with a loading dose of 250-500 mg, followed by 75-100 mg/day. Dual antiplatelet therapy is recommended for all patients with ACS for 12 months regardless of the initial revascularization strategy. Clopidogrel should be administered at first medical contact in STEMI with a loading dose of 600 mg. In patients with ACS and percutaneous coronary intervention (PCI) 2 × 75 mg clopidogrel should be given daily over 7 days, while in all other patients 75 mg per day appears to be sufficient. The two newer adenosine diphosphate-receptor antagonists prasugrel and ticagrelor lead to a more rapid and effective inhibition of platelet aggregation compared with clopidogrel, which was associated with an improved clinical outcome in two large randomized studies. Prasugrel is indicated in patients with ACS undergoing PCI and was most effective in diabetics and in patients with STEMI. In the recent TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes trial in medically treated patients with NSTE-ACS, prasugrel did not significantly reduce ischemic events compared with clopidogrel. Ticagrelor has been studied in the whole spectrum of ACS patients and reduced cardiovascular and total mortality in comparison with clopidogrel. The greatest benefit has been observed in patients with planned conservative treatment and in patients with impaired renal function. Expanding antiplatelet therapy from dual to triple therapy including a platelet thrombin receptor antagonist in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial was not associated with a significant reduction in the primary combined endpoint but an increase in bleeding complications. However, in the Thrombin Receptor Antagonist in Secondary Prevention of atherothrombotic ischemic events study in patients with prior myocardial infarction, vorapaxar on top of standard antiplatelet therapy was effective.
35 schema:genre research_article
36 schema:inLanguage en
37 schema:isAccessibleForFree true
38 schema:isPartOf N1bd74a16a169418d8a065d80c51a0b84
39 Nb8f5211b98b64f3f82f9951253bfcd12
40 sg:journal.1050274
41 schema:name Oral Antiplatelet Therapy in Acute Coronary Syndromes: Recent Developments
42 schema:pagination 47-56
43 schema:productId N47ef1b4e68c047a8ab2de897917a655c
44 N55aef63910fc46ddafdcc397dd947000
45 Nae86300865c84255a391cca6e5b66aa9
46 Nd2f3dbb7fd3645d4bb3c4046174bd863
47 Nfe5612782c764eeab4572d9e40c54d17
48 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003526860
49 https://doi.org/10.1007/s40119-013-0011-6
50 schema:sdDatePublished 2019-04-10T21:38
51 schema:sdLicense https://scigraph.springernature.com/explorer/license/
52 schema:sdPublisher N12d30d05d1e94d20940665983cbc3779
53 schema:url http://link.springer.com/10.1007%2Fs40119-013-0011-6
54 sgo:license sg:explorer/license/
55 sgo:sdDataset articles
56 rdf:type schema:ScholarlyArticle
57 N12d30d05d1e94d20940665983cbc3779 schema:name Springer Nature - SN SciGraph project
58 rdf:type schema:Organization
59 N1bd74a16a169418d8a065d80c51a0b84 schema:volumeNumber 2
60 rdf:type schema:PublicationVolume
61 N47ef1b4e68c047a8ab2de897917a655c schema:name dimensions_id
62 schema:value pub.1003526860
63 rdf:type schema:PropertyValue
64 N55aef63910fc46ddafdcc397dd947000 schema:name pubmed_id
65 schema:value 25135288
66 rdf:type schema:PropertyValue
67 N84cb2fa864364df8811cc68dac1d7dd1 rdf:first sg:person.01206257120.28
68 rdf:rest rdf:nil
69 Nae86300865c84255a391cca6e5b66aa9 schema:name readcube_id
70 schema:value 10cd095c274933c87c5b1c3779e5738c498aff8e6548016334a412503151cd7d
71 rdf:type schema:PropertyValue
72 Nb8f5211b98b64f3f82f9951253bfcd12 schema:issueNumber 1
73 rdf:type schema:PublicationIssue
74 Nd2f3dbb7fd3645d4bb3c4046174bd863 schema:name nlm_unique_id
75 schema:value 101634495
76 rdf:type schema:PropertyValue
77 Nfe5612782c764eeab4572d9e40c54d17 schema:name doi
78 schema:value 10.1007/s40119-013-0011-6
79 rdf:type schema:PropertyValue
80 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
81 schema:name Medical and Health Sciences
82 rdf:type schema:DefinedTerm
83 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
84 schema:name Clinical Sciences
85 rdf:type schema:DefinedTerm
86 sg:journal.1050274 schema:issn 2193-6544
87 2193-8261
88 schema:name Cardiology and Therapy
89 rdf:type schema:Periodical
90 sg:person.01206257120.28 schema:affiliation https://www.grid.ac/institutes/grid.413225.3
91 schema:familyName Zeymer
92 schema:givenName Uwe
93 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01206257120.28
94 rdf:type schema:Person
95 sg:pub.10.1007/s00392-011-0393-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047301868
96 https://doi.org/10.1007/s00392-011-0393-1
97 rdf:type schema:CreativeWork
98 https://doi.org/10.1016/j.ahj.2009.10.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043980215
99 rdf:type schema:CreativeWork
100 https://doi.org/10.1016/j.ahj.2010.04.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018883623
101 rdf:type schema:CreativeWork
102 https://doi.org/10.1016/j.jacc.2006.04.090 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042022467
103 rdf:type schema:CreativeWork
104 https://doi.org/10.1016/j.jacc.2010.03.100 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022669837
105 rdf:type schema:CreativeWork
106 https://doi.org/10.1016/j.jacc.2010.10.029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052574621
107 rdf:type schema:CreativeWork
108 https://doi.org/10.1016/s0140-6736(09)60441-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024369135
109 rdf:type schema:CreativeWork
110 https://doi.org/10.1016/s0140-6736(10)61088-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026699485
111 rdf:type schema:CreativeWork
112 https://doi.org/10.1016/s0140-6736(10)61273-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038812925
113 rdf:type schema:CreativeWork
114 https://doi.org/10.1016/s0140-6736(12)61269-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024204479
115 rdf:type schema:CreativeWork
116 https://doi.org/10.1056/nejmoa010746 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042739677
117 rdf:type schema:CreativeWork
118 https://doi.org/10.1056/nejmoa0706482 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000755110
119 rdf:type schema:CreativeWork
120 https://doi.org/10.1056/nejmoa0904327 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038668813
121 rdf:type schema:CreativeWork
122 https://doi.org/10.1056/nejmoa0909475 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020098070
123 rdf:type schema:CreativeWork
124 https://doi.org/10.1056/nejmoa1109719 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047539071
125 rdf:type schema:CreativeWork
126 https://doi.org/10.1056/nejmoa1205512 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001300580
127 rdf:type schema:CreativeWork
128 https://doi.org/10.1056/nejmoa1209979 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013847757
129 rdf:type schema:CreativeWork
130 https://doi.org/10.1056/nejmra052717 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040996314
131 rdf:type schema:CreativeWork
132 https://doi.org/10.1093/eurheartj/ehq320 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047347722
133 rdf:type schema:CreativeWork
134 https://doi.org/10.1093/eurheartj/ehr143 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018934044
135 rdf:type schema:CreativeWork
136 https://doi.org/10.1093/eurheartj/ehr202 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021747503
137 rdf:type schema:CreativeWork
138 https://doi.org/10.1093/eurheartj/ehr204 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035258191
139 rdf:type schema:CreativeWork
140 https://doi.org/10.1093/eurheartj/ehr236 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016275826
141 rdf:type schema:CreativeWork
142 https://doi.org/10.1160/th09-07-0482 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063292175
143 rdf:type schema:CreativeWork
144 https://doi.org/10.1161/cir.0b013e318256f1e0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052130924
145 rdf:type schema:CreativeWork
146 https://doi.org/10.1161/circulationaha.108.791061 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045157062
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1161/circulationaha.109.933796 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023849780
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1161/circulationaha.110.000786 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014740796
151 rdf:type schema:CreativeWork
152 https://www.grid.ac/institutes/grid.413225.3 schema:alternateName Klinikum Ludwigshafen
153 schema:name Klinikum der Stadt Ludwigshafen GmbH, Bremserstraße 79, 67063, Ludwigshafen, Germany
154 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...